Analysts take a look at Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) having this to say.

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Logo
Investors sentiment decreased to 0.89 in Q1 2019. Its down 0.22, from 1.11 in 2018Q4. It is negative, as 9 investors sold Catalyst Pharmaceuticals, Inc. shares while 27 reduced holdings. 12 funds opened positions while 20 raised stakes. 60.36 million shares or 24.87% more from 48.34 million shares in 2018Q4 were reported.
Pura Vida Investments Ltd Com invested in 197,594 shares or 0.33% of the stock. Meeder Asset invested in 0% or 1,703 shares. Qs Invsts Ltd Liability Corporation invested in 1,182 shares or 0% of the stock. Retail Bank Of Montreal Can holds 5,000 shares. Regions Financial has 1,000 shares for 0% of their portfolio. California Employees Retirement holds 0% or 39,532 shares. 9,063 were accumulated by Ameritas Inv Ptnrs. Dimensional Fund Advisors Lp holds 0% or 407,230 shares. Tanaka Cap has invested 3.59% in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX). Vanguard Gru has 0% invested in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) for 4.77 million shares. American Int Grp reported 0% stake. Parametric Portfolio Assocs Ltd Liability holds 0% or 186,708 shares in its portfolio. Raymond James Financial Services Advsr stated it has 0.01% of its portfolio in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX). Royal Savings Bank Of Canada reported 165,000 shares. 248,154 are held by Alps Advsrs.

Since June 11, 2019, it had 1 buying transaction, and 0 insider sales for $80,750 activity.

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Ratings Coverage

Among 3 analysts covering Catalyst Pharmaceuticals (NASDAQ:CPRX), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Catalyst Pharmaceuticals had 7 analyst reports since February 27, 2019 according to SRatingsIntel. The stock has “Buy” rating by Oppenheimer on Friday, March 1. The rating was maintained by Oppenheimer with “Buy” on Wednesday, March 20. H.C. Wainwright maintained Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) rating on Tuesday, March 19. H.C. Wainwright has “Buy” rating and $9 target. The rating was maintained by Cantor Fitzgerald on Tuesday, March 19 with “Buy”. Below is a list of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) latest ratings and price target changes.

11/05/2019 Broker: BidaskScore Rating: Buy Downgrade
01/04/2019 Broker: BidaskScore Rating: Buy Upgrade
20/03/2019 Broker: Oppenheimer Rating: Buy New Target: $10 Maintain
19/03/2019 Broker: H.C. Wainwright Rating: Buy New Target: $9 Maintain
19/03/2019 Broker: Cantor Fitzgerald Rating: Buy New Target: $10 Maintain
01/03/2019 Broker: Oppenheimer Rating: Buy New Target: $9 Maintain
27/02/2019 Broker: BidaskScore Rating: Buy Upgrade

It closed at $4.07 lastly. It is down 6.63% since July 14, 2018 and is uptrending. It has outperformed by 2.20% the S&P500.

Catalyst Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies for people with rare debilitating diseases. The company has market cap of $418.62 million. The Company’s lead product candidate is Firdapse, a proprietary form of amifampridine phosphate, which is in second Phase III clinical trials for the treatment of patients with Lambert-Eaton Myasthenic syndrome; and is in small blinded clinical trial to treat Congenital Myasthenic syndromes, as well as is in Phase II/III clinical trial for the treatment of anti-MuSK antibody positive myasthenia gravis. It currently has negative earnings. The firm also develops CPP-115, a gamma-aminobutyric acid aminotransferase inhibitor that is in Phase Ib clinical trial for the treatment of epilepsy, infantile spams, and TouretteÂ’s disorder; and CPP-109 to treat TouretteÂ’s disorder.

More notable recent Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) news were published by: Globenewswire.com which released: “Catalyst Pharmaceuticals Announces Publication of Phase 3 Clinical Trial Data for Firdapse® for the Treatment of Lambert-Eaton Myasthenic Syndrome – GlobeNewswire” on February 26, 2019, also Fool.com with their article: “Why Catalyst Pharmaceuticals, Inc. Soared in March – Motley Fool” published on April 04, 2019, Nasdaq.com published: “Catalyst Pharma Focuses on Firdapse Launch & Label Expansion – Nasdaq” on July 05, 2019. More interesting news about Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) were released by: Fool.com and their article: “Why Catalyst Pharmaceuticals Stock Is Sinking Today – The Motley Fool” published on November 29, 2018 as well as Finance.Yahoo.com‘s news article titled: “Catalyst Pharmaceuticals Posts Strong Q1 Sales for Firdapse – Yahoo Finance” with publication date: May 13, 2019.

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.